Ascendis Pharma

ASND

Market cap $15B

- Ordinary shares expected to commence trading on Nasdaq on April 20, 2026 following exchange of all American Depositary Shares (ADSs)  - ADS holders will receive one ordinary share listed on Nasdaq for each ADS held  - Simplified listing structure intended to enable enhanced depth and breadth of ownership COPENHAGEN, Denmark, April 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it plans to list its ordinary shares directly on Nasdaq, effective at the opening of trading on April 20, 2026. As part of the transition to a direct listing of ordinary shares on The Nasdaq Global Select Market, all outstanding ADSs will be exchanged for ordinary shares.

- Unprecedented improvements in arm span observed with TransCon CNP and TransCon hGH combination therapy, a measure highly meaningful to the achondroplasia community

- YUVIWEL was granted orphan drug exclusivity by U.S. FDA to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses

- Annualized height velocity of 9.05 cm/year (LS mean) for TransCon hGH-treated children was similar at Week 52 to daily somatropin-treated children  - TransCon hGH showed a safety and tolerability profile comparable to daily somatropin with no occurrences of slipped capital femoral epiphysis (SCFE) COPENHAGEN, Denmark, March 17, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced positive Week 52 topline results from New InsiGHTS, its Phase 2 randomized, open-label, active-controlled trial in the U.S. investigating the safety, tolerability, and efficacy of once-weekly TransCon hGH (lonapegsomatropin; U.S. FDA-approved for pediatric and adult growth hormone deficiency (GHD) and approved in other territories for pediatric GHD) compared to daily somatropin in prepubertal children with Turner syndrome. New InsiGHTS randomized and dosed 49 children with Turner syndrome aged 1 to 10 years old.

COPENHAGEN, Denmark, March 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from its pivotal ApproaCH Trial showing that children with achondroplasia treated with once-weekly TransCon CNP (navepegritide) maintained consistent improvements in growth through Week 104, with further improvement in body proportionality during the second year of treatment. These and other results were shared in an oral presentation by Dr. Ravi Savarirayan, M.B.B.S.

We maintain our valuation discipline and our focus on companies with competitive advantages and skilled management teams that we believe are executing better than their peers. We initiated a position in Tractor Supply after recent share weakness created a compelling entry point, in our view. Tyler Technologies was sold because the software provider's revenue growth has decelerated, which reduced our conviction in its upside potential.

Ascendis Pharma A/S (ASND) Presents at TD Cowen 46th Annual Health Care Conference Transcript

This genetic disorder treatment developer stock is nearing a buy point of a base. The biopharmaceutical got FDA approval on a new treatment.

Ascendis Pharma secured FDA approval for Yuviwel in achondroplasia, despite ongoing legal challenges from BioMarin. I expect Yuviwel's U.S. sales to be modest, with stronger international growth potential starting next year, but also meaningful competition from BridgeBio's infigratinib. The Yuviwel and Skytrofa combination demonstrates superior efficacy, positioning ASND for potential blockbuster sales in achondroplasia and other growth disorders over the long term.

Ascendis Pharma A/S (ASND) Discusses FDA Approval and Commercial Launch Plans for YUVIWEL Transcript